ALS ClinTrials May 2013 per costruzione pdf

Anakinra IL1 RA Open Safety and Tolerability Trial to Evaluate a Subcutaneous Injection Solution of 100 mg of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis Unknown NCT01277315 II Interventional Safety/Efficacy Open label Treatment Charite University, Berlin Max Planck Institute for Infection Biology Germany Thomas Meyer 20 Subcutaneous Injection Solution of 100 mg of Anakinra Number and Severity of adverse events; [ Time Frame: 1 month ] feb-11 jun-12 feb-11 The rationale of this clinical trial is based on the anti-inflammatory effect of Anakinra. One of the key mediators of inflammatory response is Interleukin-1. Anakinra is a recombinant produced Interleukin-1 receptor antagonist. This gives Anakinra anti-inflammatory attributes that presumably reduce motor neuron degeneration and disease progression.